NanoString-based breast cancer risk prediction for women with sclerosing adenosis

Breast Cancer Research and Treatment
Stacey J WinhamDerek C Radisky


Sclerosing adenosis (SA), found in ¼ of benign breast disease (BBD) biopsies, is a histological feature characterized by lobulocentric proliferation of acini and stromal fibrosis and confers a two-fold increase in breast cancer risk compared to women in the general population. We evaluated a NanoString-based gene expression assay to model breast cancer risk using RNA derived from formalin-fixed, paraffin-embedded (FFPE) biopsies with SA. The study group consisted of 151 women diagnosed with SA between 1967 and 2001 within the Mayo BBD cohort, of which 37 subsequently developed cancer within 10 years (cases) and 114 did not (controls). RNA was isolated from benign breast biopsies, and NanoString-based methods were used to assess expression levels of 61 genes, including 35 identified by previous array-based profiling experiments and 26 from biological insight. Diagonal linear discriminant analysis of these data was used to predict cancer within 10 years. Predictive performance was assessed with receiver operating characteristic area under the curve (ROC-AUC) values estimated from 5-fold cross-validation. Gene expression prediction models achieved cross-validated ROC-AUC estimates ranging from 0.66 to 0.70. Performing univariate a...Continue Reading


Nov 15, 1989·Cancer·R A JensenL W Rogers
Mar 10, 2001·Journal of the National Cancer Institute·B RockhillG A Colditz
May 15, 2001·Endocrine-related Cancer·D C AllredS A Fuqua
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenCharles M Perou
Jul 22, 2005·The New England Journal of Medicine·Lynn C HartmannDaniel W Visscher
Nov 16, 2006·Journal of the National Cancer Institute·Tia R MilaneseDaniel W Visscher
Mar 13, 2008·Journal of the National Cancer Institute·Daniel W VisscherLynn C Hartmann
Apr 30, 2010·Journal of the National Cancer Institute·Mitchell H Gail, Phuong L Mai
Jun 10, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antonio PannutiLucio Miele
Dec 17, 2010·Journal of Mammary Gland Biology and Neoplasia·Magdalena A CichonDerek C Radisky
Jan 7, 2011·Cancer Prevention Research·Fritcher Emily G BarrCarol A Reynolds
Sep 17, 2011·Cancer Prevention Research·Derek C RadiskyLynn C Hartmann
May 17, 2013·International Journal of Biological Sciences·Jing LiangHiroshi Sugiyama
Feb 11, 2014·Breast Cancer Research and Treatment·Daniel W VisscherLynn C Hartmann
Jan 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V Shane PankratzLynn C Hartmann
Jul 24, 2015·Breast Cancer Research and Treatment·Amy C DegnimDerek C Radisky
Aug 16, 2015·Cancer Prevention Research·Tina J HiekenAmy C Degnim
Feb 6, 2016·Breast Cancer Research and Treatment·Derek C RadiskyAmy C Degnim
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal


Dec 12, 2019·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Olesya ChornoguzSandra Santulli-Marotto

Related Concepts

Biological Markers
Malignant Neoplasm of Breast
Malignant Neoplasms
Gene Expression
Paraffin Embedding

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
V Shane PankratzLynn C Hartmann
Breast Cancer Research and Treatment
Jena C BergLynn C Hartmann
© 2021 Meta ULC. All rights reserved